Navigation Links
Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
Date:2/20/2008

216.0 227.8

Add: Interest expense on CODES,

net of tax 7.7 7.7

Adjusted net income, adjusted for

interest on CODES $223.8 $235.5

Diluted earnings per share

Diluted earnings per share - GAAP $1.68 $1.78

Diluted earnings per share - Adjusted $1.90 $2.00

Diluted weighted average common shares

outstanding 117.7 117.7

The reconciliation table is based in part on management's estimate of net income for the year ending December 31, 2008. Watson expects certain known GAAP charges for 2008, as presented in the schedule above. Other GAAP charges that may be excluded from adjusted net income are possible, but their amounts are dependent on numerous factors that we currently cannot ascertain with sufficient certainty or are presently unknown. These GAAP charges, such as potential asset impairment charges, are dependent upon future events and valuations that have not yet been performed.

The following table presents a reconciliation of forecasted net income for the 12 months ending December 31, 2008 to adjusted EBITDA:

Table 7

Watson Pharmaceuticals, Inc.

Forecasted Adjusted EBITDA Reconciliation Table

(Unaudited; in millions)

Forecast for

Twelve Months

Ending December 31, 2008

Low High

GAAP net income $190.3 $202.0

Plus:

Interest expense 28.2 28.2

Interest income (7.5) (6.6)

Provision
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Watson Receives FDA Approval for Generic Accuneb(R)
4. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
5. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
6. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
7. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
8. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 The new ... Spain , available today on PharmaBoardroom.com for ... Eurozone crisis that rocked the Spanish economy in 2009, and ... pharma community has remained pragmatic in times of trouble. ... still the fifth biggest European market, and the general conditions ...
(Date:9/18/2014)... A novel robotic system that can operate ... being tested as part of a biomedical research partnership ... the aim of determining if the robot, in conjunction ... faster, more accurate, less costly, and less discomforting for ... to deliver prostate cancer therapies with greater precision. , ...
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global and Chinese Stem Cell Industry Report, 2014-2017" ... are undifferentiated biological cells that can differentiate into specialized ... stem cells. Stem cell therapy can be applied to ... system disease), nervous system diseases, damage or lesion of ...
(Date:9/18/2014)... 2014  U.S. biotech company Kultevat has ... for technology developed by the Donald Danforth Plant ... including for applications in production of natural rubber in ... was developed under the direction of Roger Beachy ... president of the Danforth Plant Science Center, and is ...
Breaking Biology Technology:PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Kultevat obtains license of gene switch technology 2
... male flies of a serious agricultural pest, the medfly, have ... still embryos. Researchers writing in the open access journal ... when released into a wild population, could out-compete the normal ... stillborn protecting important crops. , Ernst A. Wimmer from ...
... GPRO ) announced today that the Company ... results on Tuesday, February 17, 2009 at,approximately 4:00 p.m. ... conference call at 4:30 p.m. ET. Hank Nordhoff, chairman ... finance, and,chief financial officer, will host the call. , ...
... 26 BioLife Solutions, Inc.,(OTC Bulletin Board: ... proprietary,GMP hypothermic storage and cryopreservation media products ... launch of its new quarterly,newsletter BioPreservation Today, ... protocols and processes, to maximize the yield ...
Cached Biology Technology:Gene-engineered flies are pest solution 2Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2008 Earnings Conference Call 2BioLife Solutions Launches BioPreservation Today(R) Industry Newsletter 2BioLife Solutions Launches BioPreservation Today(R) Industry Newsletter 3
(Date:9/18/2014)... 18, 2014 New research into the Crimean-Congo hemorrhagic ... severe hemorrhagic disease in humans similar to that caused ... CCHFV infection. This discovery has the potential to lead ... , The research, reported in a paper ... and conducted by scientists at the Texas Biomedical Research ...
(Date:9/18/2014)... times it,s demonstrated, it,s still hard to envision ... by using a signaling system called "quorum sensing," ... suit their population. In short, some bacteria "know" ... accordingly. , Once the population of quorum-sensing bacteria ... to pathogenic, or from unhelpful to helpful. The ...
(Date:9/18/2014)... built the first smartphone app that automatically reveals ... In other words, your smartphone knows your state ... and how that affects you. , The StudentLife ... loneliness to their academic performance, also may be ... to monitor mental health, trigger intervention and improve ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4
... international consortium of researchers led by Universitat Autnoma de ... studies the clinical impact of the mutations. , The ... and world distribution of some of the most frequent ... thousands of years ago and later migrated to America. ...
... A pathway whereby bacteria communicate with each other has ... Jerusalem. The discovery has important implications for efforts to ... body. Bacteria are known to communicate in nature ... molecules, said Prof. Sigal Ben-Yehuda of the Institute for ...
... device may help clinicians improve a promising cancer therapy ... such diseases as metastatic melanoma, non-Hodgkin,s lymphoma, chronic lymphocytic ... T cell transfer, has shown encouraging results in clinical ... T cells from a cancer patient, multiplying them in ...
Cached Biology News:New advances in genetic studies of Fanconi anemia patients 2Researchers predict age of T cells to improve cancer treatment 2Researchers predict age of T cells to improve cancer treatment 3
Request Info...
Agarose-LE, 250 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Agarose-LE, 500 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: